Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGGT001 in Bietti Crystalline Corneoretinal Dystrophy
NCT06706427Phase 2Active, not recruiting
- Sponsor
- Next Generation Gene Therapeutics
- Start
- Mar 2024
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of NGGT001 in Bietti crystalline dystrophy (BCD), sponsored by Next Generation Gene Therapeutics. Started Mar 2024; status: active, not recruiting.
02
Drugs
NGGT001
03
Conditions
Bietti crystalline dystrophy (BCD)
Beyond the preview
Go deeper on NCT06706427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706427.